# IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure

> **NCT06866600** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **HELP Therapeutics Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Heart Failure
- Heart Failure At NYHA Stage III or IV

## Interventions

- **BIOLOGICAL:** low dose CABG+iPSC-CMs
- **BIOLOGICAL:** High dose CABG/LVAD+iPSC-CMs
- **OTHER:** CABG/LVAD+Saline

## Key facts

- **NCT ID:** NCT06866600
- **Lead sponsor:** HELP Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06866600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06866600, "IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06866600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*